DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Daniel Sundheim's - 1 Sundheim - 1 Philip Morris - 1 Tessa Romero - 1 Lexeo - 1 Romero - 1 LX2020 - 1 LX1001 - 1
Top related locs:
U.S Amazon Vegas Sands DDOG India Ingersoll
Top related orgs:
Lexeo Therapeutics - 3 Nvidia - 2 JPMorgan - 2 Meta - 1 Viking Global - 1 Mastercard - 1 WWE - 1 UFC - 1

Search resuls for: "Lexeo"


7 mentions found


☆ Sundheim's D1 hedge fund shook up its tech exposure, including selling the hottest stock right now
  + stars: | 2024-02-14 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Daniel Sundheim's D1 Capital made a handful of notable changes to its technology holdings in the fourth quarter, including closing out a position in a key artificial intelligence play. Sundheim also zeroed out his stake in software stock Salesforce , while trimming Microsoft and Facebook parent Meta by more than 60% and 20%, respectively. The role of large-cap tech stocks in driving up the market was so apparent that a group was dubbed the "Magnificent 7" for its outsized gains. Outside of big tech, Sundheim added to Mastercard and Philip Morris stakes. On the flip side, he dissolved stakes in a number of well-known stocks including Hilton , Las Vegas Sands , Liberty Media and Yum Brands .
Persons: Daniel Sundheim's, Sundheim, Philip Morris Organizations: Nvidia, Facebook, Meta, Viking Global, Mastercard, WWE, UFC, Lexeo Therapeutics, Hilton, Liberty Media, Yum Brands, Rivian, Electric Locations: Amazon, Vegas Sands
☆ This biotech stock targeting genetically driven diseases could nearly double, predicts JPMorgan
  + stars: | 2023-11-28 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +3 min
Lexeo Therapeutics ' stock could nearly double as its gene therapies advance through its pipeline, according to JPMorgan. That implies a potential upside of nearly 82% from the stock's Monday closing price of $11. LXEO ALL mountain Lexeo Therapeutics all-time stock chart Analyst Tessa Romero cited Lexeo Therapeutics' lead cardiac therapy, LX2006, as a catalyst for the stock. The gene therapy is delivered to body tissues through an adeno-associated virus vector and it targets a rare genetic heart disorder called Friedreich's ataxia cardiomyopathy. The firm is also evaluating a similar type of gene therapy, LX2020, to treat cases of PKP2-ACM, another kind of inherited heart disease.
Persons: Tessa Romero, Lexeo, Romero, LX2020, LX1001, – LX2006, Michael Bloom Organizations: Therapeutics, JPMorgan, Lexeo Therapeutics, ACM, ~$ Locations: U.S
☆ Here are Tuesday's biggest analyst calls: Apple, Rivian, Nvidia, Boeing, Affirm, Datadog, Amazon & more
  + stars: | 2023-11-28 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Here are Tuesday's biggest calls on Wall Street: UBS downgrades ChargePoint to neutral from buy UBS said it's cautious on the EV charging company's growth outlook. " Citi reiterates Nvidia as buy Citi said it's sticking with its buy rating on shares of Nvidia. " Wells Fargo downgrades Booz Allen Hamilton to equal weight from overweight Wells said investors should wait for a better entry point for the defense contractor. Raymond James upgrades Crocs to strong buy from outperform Raymond James said it sees an attractive entry point for the show company. Wells Fargo reiterates Amazon as overweight Wells said international trends for Amazon remain healthy.
Persons: UBS downgrades ChargePoint, it's, Wells, Booz Allen Hamilton, Bernstein, Raymond James, Crocs, CROX's, Estee Lauder, Jefferies, underperform Jefferies, Evercore, Rivian, Piper Sandler downgrades Shopify, Piper, Piper Sandler, Canaccord, TD Cowen, Datadog, TD, Truist, it's bullish, Ingersoll Rand Organizations: UBS downgrades, UBS, JPMorgan, Apple, Citi, Nvidia, HSBC, RBC, Boeing, Lexeo Therapeutics, Bank of America, Virtu, Logistics, Industry Locations: U.S, DDOG, India, Ingersoll
☆ The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease
  + stars: | 2023-01-20 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +6 min
But amid some positive news, companies focused on Alzheimer's have said they've received an influx of investor interest. In trials, Leqembi was found to slow the rate of cognitive decline by 27% in Alzheimer's patients over 18 months. Eli Lilly's drug donanemab is expected to have data soon but just faced a setback from the FDAEli Lilly's donanemab is the focus of a late-stage trial. In the first half of this year, Eli Lilly is expected to release data for its Alzheimer's drug donanemab, which is being tested in a late-stage trial. Getty ImagesAduhelm, the first Alzheimer's drug to be approved in 18 years, was OK'd by the FDA in 2021 but has faced controversy.
☆ Here's where to look for the next developments in the fight against Alzheimer's disease
  + stars: | 2023-01-17 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +10 min
The Centers for Disease Control and Prevention estimates 5.8 million Americans were living with the disease in 2020 . BIIB 6M mountain Biogen's stock is trading well above its lows Leqembi treats Alzheimer's disease by targeting amyloid-beta plaques in the brain. Attention shifts to Eli Lilly Shares of other Alzheimer's drug developers have often mirrored Biogen's moves. Small drug developers Smaller Alzheimer's drug developers have also been boosted by research developments. Still in an early stage of its research, Prothena has traded as a proxy for developments in Alzheimer's treatment.
☆ The FDA just approved a new Alzheimer's drug that's set to be a blockbuster
  + stars: | 2023-01-06 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +6 min
The FDA just approved a new treatment for Alzheimer's disease from Eisai and Biogen. Alzheimer's disease affects roughly 6.5 million Americans and has no cure. The FDA granted an accelerated approval of the drug, meaning the companies will have to conduct additional follow-up studies. While the drug has been approved, questions about cost remainWhile Leqembi has been approved by the FDA, the drug will have to face other key hurdles before it becomes widely available to patients. Aduhelm, an Alzheimer's drug also developed by Biogen and Eisai and approved by the FDA in 2021, failed to garner support from the Centers for Medicare and Medicaid Services, even after it was approved by the FDA.
☆ The 10 people transforming healthcare, from companies like Moderna, Humana, and Lexeo Therapeutics
  + stars: | 2022-11-21 | by ( Business Insider | ) www.businessinsider.com   time to read: 1 min
Elisabeth Bik, microbiologist, scientific integrity consultant, Harbers BikHelynn Ospina/InsiderIn June 2013, as she was working as a research associate at Stanford University, Elisabeth Bik noticed that someone had plagiarized some of her work in a book chapter. Since then, Bik has made a career out of exposing doctored images and other information manipulation in scientific information. "I feel I can be the voice of a lot of people without power to raise these concerns because I don't really care if a person is the dean of a big university or the editor in chief of a journal," she told Insider.
0 next >>
Total: 7